Chak Balijepalli, MD, PhD Partner, Managing Director
Chak has more than 15 years of experience in HEOR and clinical epidemiology. Chak’s therapeutic experience includes oncology, cardiovascular disease, metabolic diseases, psychiatry, rheumatology, and rare diseases, with publications in leading journals, including Diabetes Obesity and Metabolism, Cardiovascular Diabetology, Clinical Epidemiology, Hypertension Research, Schizophrenia Research, and European Archives of Psychiatry, and Clinical Neuroscience. Chak has led and supported clients globally with HEOR projects leading to reimbursement submissions to CADTH, NICE, SMC, HAS, and iQWIG. Chak has also worked in several internationally recognized epidemiological research projects including the German National Cohort study, and the Heinz Nixdorf Recall study, and is an active collaborator with academic institutions in Germany. Chak has received his doctoral degree in epidemiology from University of Duisburg Essen, Germany, and a medical degree from NTR University in India.
Eric Druyts, MScPartner, Managing Director
Eric has more than 15 years of experience in HEOR. He is a global expert in health technology assessment, having supported clients with reimbursement submissions to NICE, SMC, IQWiG, NoMA, HAS, and CADTH, in a wide-variety of therapeutic areas, including but not limited to oncology, diabetes, cardiovascular disease, rare diseases, and hepatitis. Eric is also a leading methodologist, having led or advised on more than 400 systematic reviews, 200 comparative effectiveness analyses (e.g. network meta-analysis, matching-adjusted indirect comparisons) and 100 economic evaluations (e.g. cost-utility analyses, budget impact models). Eric has completed graduate work in health technology assessment, evidence synthesis, and health economics at the University of British Columbia, the University of Victoria, the University of Oxford, and the University of Glasgow. He has published over 75 peer-reviewed papers.
Michael Marentette, MBAVice President, Head of Business Development
Michael is a senior HEOR and market access leader with 25+ years of experience in the pharmaceutical industry, including 15+ years with brand pharma, 10+ years in consulting, and 5+ years in global and Canadian HEOR and market access business development. Most recently, Michael was Senior Principal, HTA & Evidence Synthesis, at Medlior Health Outcomes Research. Prior to that, Michael was Country Manager and Senior Director, Market Access, at Complete HEOR Solutions (CHEORS), a global HEOR consultancy. Michael’s pharmaceutical industry experience includes 15 years at Merck and Janssen in HEOR and market access, including the position of Director, Reimbursement Planning, and has worked on multiple brands across multiple therapeutic areas. Michael holds an MBA in Management Science from McGill University in Montréal, Québec. Michael is fluent in both English and French.